Major surgery within  weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery)
Major surgery within  weeks of study entry; minor surgical procedures (e.g., port insertion) are not excluded, but sufficient time should have passed for wound healing (as determined by the treating investigator)
INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring twilight sedation such as endoscopies or mediport placement may only require a -hour waiting period, but this must be discussed with an investigator
INCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring twilight sedation such as endoscopies or mediport placement may only require a -hour waiting period, but this must be discussed with an investigator
Any major surgery must be completed at least  weeks prior to study entry; minor surgical procedures (except insertion of vascular access device) must have been completed at least  weeks prior to study entry
Minor surgical procedures within  days of baseline, or not yet recovered from prior surgery.
Surgery within  weeks prior to study registration except for minor procedures. NOTE: Hepatic biliary stent placement is allowed. NOTE: Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.
Major surgery within  months prior to enrollment or minor surgery within  days of the first day of treatment
Major surgery within  weeks or minor surgery within  weeks before registration or scheduled for surgery during the projected course of the study; wounds will be completely healed prior to study entry and patients recovered from all toxicities from surgery; placement of vascular access device is not considered major or minor surgery in this regard
Patients who have undergone major surgery <  weeks or minor surgery <  weeks prior to registration; wounds must be completely healed prior to study entry and patients recovered from all toxicities from surgery; placement of a vascular access device is not considered major or minor surgery in this regard
Patients may not have had major surgery within  days of enrollment, or minor surgery within  days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
Major surgery within  days before enrollment; biopsies and line placement procedures are not exclusion criteria
History of major surgery within  weeks or minor surgery within  week of roflumilast administration; major surgery includes, for example, any open or laparoscopic entry into a body cavity, or operative repair of fracture; minor surgery includes, for example, open surgical biopsy of palpable/superficial lymph node, or placement of vascular access device
Major surgery within  weeks of first dose of study medications. Minor procedures (e.g. port placement, endoscopy with intervention) within  weeks of first dose of study medications are allowed
Known bleeding risk including serious hemorrhage or hemoptysis within the last  months; major surgery within the past  weeks or minor surgery within the past  weeks
Major surgery within  weeks of first dose of study medications; minor procedures (e.g. port placement, endoscopy with intervention) within  weeks of first dose of study medications
Any surgery (not including minor diagnostic procedures such as lymph node biopsy) within  weeks of baseline disease assessments; or not fully recovered from any side effects of previous procedures; an interval of  week for stereotactic brain biopsy from the start of study treatment is acceptable
Any major surgery within  weeks, minor surgery within  weeks or other minor procedures requiring light sedation, such as endoscopies or mediport placement, within  hours prior to initiation of study treatment
Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring conscious sedation such as endoscopies or mediport placement may only require a -hour waiting period, but this must be discussed with an investigator
Prior surgery: patients may not have had major surgery within  days of enrollment, or minor surgery within  days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring Twilight sedation such as endoscopies or mediport placement may only require a -hour waiting period, but this must be discussed with an investigator
Major surgery within prior  weeks and minor surgery within  days;
Major surgery in the last two weeks of starting study therapy; this does not include procedures like biopsy (needle or excisional) or port placement as these are not considered as major surgery
Major surgery (such as GI surgery) within  weeks of enrollment; however, subjects who have had a nephrectomy may be enrolled  weeks after surgery, providing there are no wound-healing complications; subjects with clinically relevant ongoing complications from prior surgery are not eligible; the following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Had surgery within  weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)
All adverse events grade =<  related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia or neuropathy; patients are eligible for enrollment if they have had no surgery in the prior  weeks (minor surgical procedures such as skin biopsies and port placement done on an outpatient basis do not require a waiting period)
Surgery (including open biopsy), significant traumatic injury within  days prior to randomization, minor surgery, including insertion of an indwelling catheter, within  hours prior to the first bevacizumab infusion is allowed
Any of the following prior therapies:\r\n* Radiation to >= % of bone marrow\r\n* Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =<  weeks prior to registration; minor surgery =<  weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard
Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring Twilight sedation such as endoscopies or mediport placement may only require a  hour waiting period, but this must be discussed with an investigator
Have undergone major surgery within  days prior to first dose of AP. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.
Major surgery as defined by the investigator within  weeks of the first dose of study treatment (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery)
Minor surgery within  days of first dose of STA-
Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; at least  weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay required for minor procedures (e.g., tumor fine-needle aspiration [FNA] or core biopsy, venous access device placement)
Ibrutinib must be discontinued  days before (when possible) until  days after major surgery, and  days before (when possible) until  days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery >  days before initiating treatment, and/or must have completed minor surgery >  days before initiating treatment
At least  weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor procedures (e.g., tumor core biopsy)
Major surgery within  days of study treatment; minor surgery within  weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
Major surgery within  days of study treatment; minor surgery within  weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
At least  weeks must have elapsed since the patient underwent any major surgery (eg. MAJOR: laparotomy, laparoscopy, thoracotomy, VATS [video assisted thorascopic surgery]); there is no restriction on MINOR procedures: (eg. central venous catheter placement, ureteral stent placement or exchange, tumor core or fine-needle aspirate [FNA] biopsy)
At least  days since any minor surgery such as port placement
Patients must not have had a previous surgical resection; however, patients may have undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgery for the purpose of determining the diagnosis, stage or potential resectability of newly diagnosed lung tumor; at least  days must have elapsed since thoracic surgery (excluding mediastinoscopy or other minor surgeries) and patients should have recovered from all associated toxicities at the time of registration; patients must not be planning to undergo a minor surgical procedure while on this study
Has had major surgery within  weeks prior to enrollment NOTE: Minor surgery (e.g., minor biopsy, central venous catheter placement) is permitted within  weeks prior to enrollment.
Had major surgery within  days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.
Major surgery within  days before first dose or a scheduled surgery during study period; insertion of a venous access device (eg, catheter, port) is not considered major surgery.
Known need for major surgery within  days of the first dose of Ribociclib. Gastrostomy, insertion of a G tube, Ventriculo-peritoneal shunt, endoscopic ventriculostomy and central venous access are NOT considered major surgery.
At least  weeks must have elapsed since the patient underwent any major surgery (e.g., major: hysterectomy, resection of a lung nodule; minor: central venous access catheter placement).
Patients may not have had major surgery within  days of enrollment, or minor surgery within  days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
Major surgery =<  weeks prior to registration; minor surgery =<  weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery; subjects must have recovered from all surgery related toxicities to =< grade  or to baseline if subject started with > grade  toxicity, not otherwise violating the above inclusion criteria
Patients must not have had major surgery within  weeks prior to enrollment on the high risk stratum; patients with history of recent minor surgical procedures (vascular catheter placement, bone marrow evaluation, laparoscopic surgery, liver tumor biopsy) will be eligible
Major surgery within  weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)
Adequate recovery from all recent surgery is required; at least  week must have elapsed from the time of a minor surgery; at least  days must have elapsed from the time of a major surgery. Patients must have recovered from all surgery-related toxicities to Grade  or less.
Subjects enrolling on the ibrutinib arm must not have had major surgery within  days, or minor surgery within  days
Major surgery (such as GI surgery) within  weeks of enrollment; however, subjects who have had a nephrectomy may be enrolled  weeks after surgery, providing there are no wound-healing complications; subjects with clinically relevant ongoing complications from prior surgery are not eligible; the following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Surgery within  weeks prior to study treatment except for minor procedures: NOTES: Hepatic biliary stent placement is allowed. Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.
Major surgery within  days prior to start of treatment; no time limitations after minor surgery (e.g.: core biopsy or central line placement)
Patients may not have had major surgery or radiotherapy (therapeutic and/or palliative) within  days prior to initiation of study treatment, including CNS-directed radiation therapy; minor procedures, such as tumor biopsy, thoracentesis, or intravenous catheter placement are allowed with no waiting period
Any minor surgery or core biopsy completed >=  week prior to randomization and patient must have fully recovered from the procedure; Note: insertion of a vascular access device is not considered major or minor surgery
The patient has had minor surgery ?  days from the start of study treatment (excluding the placement of central/peripheral lines, skin biopsy).
Major surgery within  weeks or minor surgery within  days of the first day of study drug dosing
Major surgery <  weeks or minor surgery (e.g. talc pleurodesis, excisional biopsy, etc) <  weeks prior to the first day of study defined treatment
Patients should have completed any major surgery >=  weeks prior to registration and must have completed any minor surgery >=  weeks prior to registration; patients must have fully recovered from the procedure\r\n* The following are examples of procedures considered to be minor: port placement, laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and dental extraction procedures\r\n* Insertion of a vascular access device, thoracentesis, paracentesis, and endoscopic ultrasonographic procedures are not considered to be major or minor surgeries
Recovery from any major or minor surgeries
Recovery from any major or minor surgeries; patient must be  weeks post-major surgery and  weeks post-minor surgery
Minor surgery <  weeks from the start of treatment; (insertion of a vascular access device is not considered major or minor surgery)
Patients should have completed any major surgery or open biopsy >=  weeks from start date of chemotherapy; patients must have completed any minor surgery or core biopsy >=  week prior to first dose of bevacizumab; (insertion of a vascular access device is not considered major or minor surgery)
At least  weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor procedures (e.g., central venous access catheter placement)
Major or minor surgery <  and < days from the start of treatment, respectively;
Major surgery (not including minor diagnostic procedures such as lymph node biopsy) within  weeks of start of study drug; or not fully recovered from any side effects of previous procedures
Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring twilight sedation such as endoscopies or Mediport placement may only require a -hour waiting period, but this must be discussed with an investigator
Adequate recovery from recent surgery; at least one week must have elapsed from minor surgery (placement of venous access device or fine needle aspiration) and at least  weeks from major surgery
Patients may not begin protocol therapy within  days of major surgery or within  days of minor surgery
Major surgery requiring general anesthesia within  days or minor surgery within  days of study enrollment; subjects must have recovered from surgery related toxicities
Patients that have had major surgery =<  weeks or minor surgery (e.g. talc pleurodesis, excisional biopsy, etc) =<  week prior to the first day of study defined treatment
Major surgery (with the exception of minor surgical procedures, such as catheter placement or tumor biopsy) within  days prior to the first dose of ponatinib
Ibrutinib must be discontinued  days before (when possible) until  days after major surgery, and  days before (when possible) until  days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery within  weeks before initiating treatment, and/or must have completed minor surgery >  days before initiating treatment
Major surgery within  days of study treatment; minor surgery within  weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
Surgery (except minor surgeries,e.g., biopsies) or radiotherapy
Major surgery (i.e., the opening of a major body cavity, requiring the use of general anesthesia) within  weeks before enrollment; minor surgery (except for insertion of vascular access device) within  weeks before enrollment; or not yet recovered from the effects of the surgery.
Minor procedures (such as a central line placement, needle biopsy, thoracentesis, or paracentesis) =<  days prior to registration
Recovery from effects of recent surgery, radiotherapy, or chemotherapy; patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI]); any other prior therapy such as radiation therapy, tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormone therapy, must be discontinued at least  days prior to the first dose of pazopanib; at least  days must have elapsed since the patient underwent any major surgery (laparotomy, laparoscopy, thoracotomy, video assisted thorascopic surgery-VATS); no restriction on minor procedures (central venous access catheter placement, ureteral stent placement, thoracentesis)
Major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last  days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery.
Major surgery within  weeks of study entry; minor surgical procedures (e.g. port insertion, pleurex catheter placement) are not excluded, but sufficient time should have passed for wound healing
